US FDA Crossing Off More Foreign OTC Firms On Globalization Checklist
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
FDA issued 39 warning letters to OTC drug facilities, most of them outside the US, in 2017, a number significantly boosted by an initiative to inspect a total of 1,000 foreign drug manufacturers from January 2017 through September 2019 , says CDER compliance director Donald Ashley. Many GMP violations behind FDA's warning letters concerned “rudimentary" requirements.
You may also be interested in...
Warnings Up As FDA Trims Its List Of Uninspected OTC Drug Manufacturers
Hundreds of foreign OTC drug firms marketing products in US had not been inspected for GMP compliance before FDA Safety and Innovation Act of 2012 pointed agency toward crossing those facilities off its list. Of the foreign OTC facilities inspected between June 2016 and January 2018, 25% received "official action indicated" inspection results, prompting warning letters and import alerts.
Manufacturing Compliance Updates In Brief From US FDA And The EU
FDA issues five more drug GMP warning letters to drug manufacturers and active ingredient manufacturers at sites in India, China, and the US exhorting them to do a better job of testing ingredients and final products and to manage cross-contamination risks better. UK MHRA withdraws the GMP certificate for one Taiwanese API maker for its lack of knowledge of sterile processing. Meanwhile, FDA adds an Indian facility to its drug GMP import alert.
Manufacturing Compliance Updates In Brief From US FDA And EU
After import alerts to five facilities in China, Austria, and Australia, US FDA follows up with warning letters; meanwhile, another firm in China receives notice of non-compliance with EU GMP requirements.Shanwei Honghui, Wuham Moxibustion, Yicheng Chemical, Schrofner Cosmetics, Delta Labs, and Inner Mongolia Changsheng among firms now in regulatory cross hairs.